Nektar receives $19.75M payment


Pursuant to its license, manufacturing and supply agreement with Ophthotech for certain aspects of its PEGylation technology to develop, manufacture and sell Fovista, Nektar Therapeutics (NKTR) receives a $19.75M payment from its partner.

On May 19, 2014 Ophthotech entered into a licensing and commercialization agreement with Novartis (NVS) for Fovista. Pursuant to this contract, Novartis paid Ophthotech a $200M upfront fee. This was the basis for paying $19.75M to NKTR.

NKTR is entitled to as much as $9.5M in additional payments from Ophthotech based on its achievement of certain regulatory and sales milestones plus low- to mid-single digit royalties on net sales of Fovista.

From other sites
Comments (1)
  • Scrying Biotech
    , contributor
    Comments (2740) | Send Message
     
    It's the year of NKTR.
    18 Jun 2014, 06:50 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs